Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Pregnancy Testing in Gynaecology patients (316)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Pregnancy Testing in Gynaecology patients (316)

Warning

Objectives

To standardise practice in testing for pregnancy in women attending gynaecology

Scope

When to perform pregnancy testing in women undergoing procedures, investigations, treatments and surgical procedures in the inpatient and outpatient setting including those undergoing general anaesthetic

Audience

All Healthcare workers involved in the care of women where pregnancy status would affect care

Please report any inaccuracies or issues with this guideline using our online form

All patients of childbearing potential (biologically female and aged 12 - <55 years of age) should have pregnancy status determined prior to undergoing anaesthetic, some radiological investigations, surgery under general anaesthetic, or a procedure which may lead to potential disruption of a pregnancy through instrumentation of the uterus.

Pregnancy status should also be determined in women when presenting as an emergency to hospital where pregnancy may determine diagnosis or affect management of these women.

For further details regarding pregnancy testing in girls aged 12-16 years of age, please refer to the RHC guideline Pregnancy testing guidelines for girls aged 12 yrs & over (RHC) 

This guidance is mandatory – every eligible patient must be assessed, every time.

Gaining Consent

NICE suggest that on the day of the procedure or at time of presentation, all women of childbearing potential should have a sensitive discussion as to whether there is any possibility they could be pregnant.  The healthcare professional, should make the patient aware of the risks that both the anaesthetic and the procedure itself can have on the developing pregnancy.

Permission should be sought from the patient to perform the test.  Covert pregnancy testing should not be undertaken as it can be viewed as an infringement of human rights.  Discussions regarding pregnancy testing should be documented in notes.

Routine Urine Pregnancy Testing versus Enquiry Based Assessment

There are two possible options for ascertaining pregnancy status in female patients; consented urine pregnancy testing or Enquiry Based Assessment.

The urine pregnancy test should be considered as first line approach and can be used in conjunction with enquiry based approach.  In cases when urine testing is not possible, practical or feasible, e.g. adults with incapacity, enquiry based assessment alone should be performed and documented.

Information for Enquiry Based assessment includes

  • First day of Last Menstrual Period (LMP)
  • Current contraception and usage
  • Date of last episode of unprotected Sexual Intercourse (UPSI)

The criteria for excluding pregnancy used by the Faculty of Sexual and Reproductive Health is outlined below.

Criteria for excluding pregnancy (adapted from UK Selected Practice Recommendations for Contraceptive Use) 3

Health professionals can be ‘reasonably certain’ that a woman is not currently pregnant if any one or more of the following criteria are met and there are no symptoms or signs of pregnancy: 

  • She has not had intercourse since last normal menses
  • She has been correctly and consistently using a reliable method of contraception
  • She is within the first 7 days of the onset of a normal menstrual period
  • She is not breastfeeding and less than 4 weeks from giving birth
  • She is fully breastfeeding, amenorrhoeic, and less than 6 months’ postpartum
  • She is within the first 7 days post-abortion or miscarriage.

Who should participate in testing?

  • Patient who present to emergency gynaecology services
  • Patients attending for radiological investigations excluding ultrasound
  • Patients undergoing general anaesthetic, including non-gynaecological procedures
  • In the outpatient gynaecology setting, when undertaking procedures where there is instrumentation of the uterus pregnancy status should be determined.  This would include hysteroscopy, pipelle endometrial biopsy, insertion or removal of intrauterine contraceptive devices and LLETZ procedures.
  • Consideration should be given to pregnancy testing prior to administration of hormonal therapies such as contraception or GnRH analogues.

Who is exempt from testing?

The only patients who can be excluded are as follows:

  • Previous total hysterectomy
  • Patients attending for procedure where pregnancy already confirmed e.g. TOP patients, patients management of a miscarriage including MVA and patients undergoing management of ectopic pregnancy

In women where there is contraception use, HRT use and women who are post-menopausal and <55years of age, testing should still be considered and carried out.

How is the test carried out?

Testing should be carried out on the day of the procedure, using a sample collected on admission for the procedure.  High sensitivity urine pregnancy tests should be used which will identify HCG >25iu/l.

The result of the pregnancy test must be recorded in the peri-operative care plan or in the patient notes.  It should include the test kit lot number.

In the theatre setting, the operating surgeon and theatre staff must be informed of any positive result prior to theatre transfer.  The test result, positive or negative, must be included in the surgical pause.

Limitations of Urine pregnancy Testing

It should be acknowledged that the Urine Pregnancy Test adds weight to exclusion of pregnancy, but only if ≥ 3 weeks since UPSI.

Clinicians should consider the risk of becoming pregnant if UPSI < 7 days.  In these cases an assessment should be made with regard to continuing with the planned procedure or rearranging.

Pregnancy test flow chart

Risk of pregnancy flow chart

This guidance is mandatory – every eligible patient must be assessed, every time.

Editorial Information

Last reviewed: 10/06/2024

Next review date: 31/03/2028

Author(s): Dr Claire Higgins, Consultant Obstetrics and Gynaecology.

Version: 3

Approved By: Gynaecology Clinical Governance Group

Document Id: 316

References

1. NHSGGC, Pregnancy testing guidelines for girls aged 12 yrs & over (RHC)

2. Routine preoperative tests for elective surgery, NICE guideline, [NG45] Published April 2016

3. Faculty of Sexual and Reproductive Healthcare, Clinical Guidance, Intrauterine Contraception, April 2015, (amended September 2019).

4. Alere TM HCG Casette (25mIU/ML), Product information sheet